ATRX and soft tissue sarcoma: Together, these findings demonstrate that Atrx deletion impaired CGAS/STING response to HSV-1 dsDNA and increased susceptibility to oncolytic herpesvirus therapy in multiple human and mouse models of soft tissue sarcoma.